The demographics of actual data from the NNMC IATS are summarized in Table 3.
Linear regression analysis demonstrated close correlation between the costs based on actual case data (Modified Cross-Trained model) and those of the theoretical Cross-Trained model (Fig. 3). Specifically, the regression line for the Cross-Trained model versus Actual Cost (CT = 1.1x − 2172) more closely matched the equation for ideal correlation (y = x) than did any other model. This Modified Cross-Trained model was more economical than the Fully Outsourced model when annual caseload exceeded 55 cases, and closely matched the prediction of the Cross-Trained model.
The cost of perioperative allogeneic blood is significant (1) and has led to the development of techniques to reduce allogeneic transfusion. These strategies have included preoperative autologous blood donation, induced hypotension, hemodilution, pharmacological drugs such as aprotinin and erythropoietin, and perioperative salvage both with and without washing. However, these techniques have risks, unclear benefit, and/or are expensive. Fibrin split products in unwashed blood may activate both coagulation and fibrinolysis (13). Hemodilution may be beneficial (14–16), but does not help in acute, unanticipated hemorrhage. Autologous predonation exceeds the costs of allogeneic blood, and requires time, planning, and patient cooperation (17). Aprotinin costs approximately $1000 per dose and is associated with allergic reactions upon re-exposure (18) whereas recombinant erythropoietin can cost 4 times as much (17). Intraoperative salvage is an attractive alternative because it is available quickly, is free of viral contamination, and does not suppress the immune system. However, this expensive service requires dedicated personnel and equipment.
Many investigators (2–9) have questioned the value of an IATS because of this expense and the perceived safety of contemporary blood banking (19). Although one of these studies considered the additional costs of treating transfusion-related complications (4), the analysis only included transfusion reactions and viral disease transmission. Treating bacterial infections related to transfusion-induced immunosuppression was not analyzed, but two studies (20,21) have reported increased hospital costs of $300 to $1000 per unit of allogeneic blood transfused. Furthermore, these studies did not question whether there were more economical means of obtaining an IATS.
The presented analysis, although timely given contemporary medico-economics, has limitations regarding several cost and complication assumptions. The price anonymity is not scientifically satisfying, although an economic (and, perhaps, legal) necessity. Also, these price assumptions may be subject to geographic, volume, and shift-premium discrepancies that were not considered in the projections. However, these additional fees did not alter the accuracy of the model when applied to actual data from the NNMC IATS with shifts and multiple cases considered.
The assumption of one case per day may seem unrealistic, especially to a hospital with a large surgical volume, but it still provides a useful starting point for cost comparisons. If operating room managers consider an IATS service analogous to other essential pieces of surgical equipment and services (such as laparoscopic equipment, neuromonitoring, intensive care unit bed availability, and transesophageal echocardiography), then flexible scheduling of elective cases makes this assumption more realistic, and is substantiated anecdotally by the IATS data from the NNMC. Although all these differences may alter the efficiency of the presented models, adjusting the variables accordingly still helps a hospital determine its best strategy for obtaining an IATS, which was an objective of this study.
This analysis also did not consider the costs of training technicians, of their loss to their primary workspaces, and of their medical direction. Device manufacturers may include training as part of the machine purchase price. Inability to perform primary duties while cross-covering as an IATS technician is a valid concern. However, IATS duties require approximately 10–15 minutes each for equipment setup and breakdown, plus approximately 10 minutes to process each unit of cell salvage blood. It is not unrealistic to postpone or have another person temporarily cross-cover the other, less critical duties. And, although the salary of the medical director would impact the overall cost of an IATS, medical direction is required by the American Association of Blood Banks (22) regardless of the model chosen. Therefore, this salary is validly negated from each model without affecting their relative cost effectiveness.
This analysis did not consider rebates offered by manufacturers. As reported by Green (23), device manufacturers may lend machines (or discount list prices) as part of a disposables purchase agreement. Either of these rebates would further improve the efficiency of all but the Fully Outsourced model.
Related to the costs of equipment are the issues of machine lifespan and discounting the costs over time. The authors chose eight years as the lifespan of these machines, which was both arbitrary and consistent with another study (10). As machine lifespan increases, the costs of all but the Fully Outsourced model decrease. Likewise, discounting the machine costs over the eight-year projected lifespan would decrease costs in all but the Fully Outsourced model. Discounting was not applied in these (year 1) models because the discount rate does not apply to the year 1 costs (24).
This study did not consider the costs of treating complications caused by allogeneic or cell salvage blood. A major benefit of an IATS is avoiding the infectious complications associated with allogeneic blood. Although analyzing the costs of treating bacterial infections attributed to allogeneic transfusion is interesting, data have only been reported for hip arthroplasties (20) and colorectal resections (21) and are not easily extrapolated to the entire case-variety and patient population of an individual hospital. The better-documented cost of treating viral diseases also was not considered. These costs, fascinating from the standpoint of global health system economics, may be better quantified with a quality adjusted life year analysis (25). This technique was not used in this study because the results may not practically affect an individual hospital’s decision to obtain an IATS unless that facility was absorbing the costs of these complications. Finally, no complex medical procedure, including those of an IATS, is risk free. However, there are no published data on the incidence of mishaps with these devices. A study of the incidence of these complications, their costs, and a comparison to those associated with allogeneic blood is long overdue, and could possibly impact a hospital’s decision to obtain an IATS.
Cross-training a current employee with bonus compensation is the most efficient model when annual caseload exceeds 55 cases per year. Anesthesiology technicians can ideally fill this role. Two of the authors (DFS and PSP) have successfully managed IATS with this model. Anesthesiologists are ideally positioned to lead autotransfusion services because of their operating room presence and transfusion therapy experience. Physician leadership of a hospital’s IATS, mandated by the American Association of Blood Banks (22), is consistent with the concept of the perioperative physician providing a “value-added” service (23). Physician leadership and the establishment of detailed guidelines are essential to the quality assurance of intraoperative erythrocyte salvage—a service described in an editorial as a “largely unregulated cottage industry”(26).
In summary, cross-training a current employee with bonus compensation is the most efficient IATS model when the annual caseload exceeds 55 cases. The Fully Outsourced model is more efficient with smaller caseloads. The financial assumptions for the cross-training model quickly break down if the case volume is large enough to necessitate hiring an additional technician. When case volume increases to this point, the costs become those of the New Employee model. Avoiding nonviral and bacterial infections associated with allogeneic transfusions may be of even greater value than this simple “make versus buy” analysis demonstrates, but this hypothesis requires further research.
1. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84: 3:732–47.
2. Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair: an analysis of cost and benefit. J Vasc Surg 1996; 24: 213–8.
3. Huber TS, Carlton LC, Irwin PB, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction. J Surg Res 1997; 67: 14–20.
4. Huber TS, McGorray SP, Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. J Vasc Surg 1997; 25: 984–93.
5. Mah ET, Davis R, Seshadri P, et al. The role of autologous blood transfusion in joint replacement surgery. Anaesth Intensive Care 1995; 23: 472–7.
6. Simpson MB, Georgopoulos G, Eilert RE. Intraoperative blood salvage in children and young adults undergoing spinal surgery with predeposited autologous blood: efficacy and cost effectiveness. J Pediatr Orthop 1993; 13: 777–80.
7. Siller TA, Dickson JH, Erwin WD. Efficacy and cost considerations of intraoperative autologous transfusion in spinal fusion for idiopathic scoliosis with predeposited blood. Spine 1996; 21: 848–52.
8. Cavallieri S, Riou B, Roche S, et al. Intraoperative autologous transfusion in emergency surgery for spine trauma. J Trauma 1994; 36: 639–43.
9. Guerra JJ, Cucker JM. Cost effectiveness of intraoperative autotransfusion in total hip arthroplasty surgery. Clin Othop 1995; 315: 212–22.
10. Haynes SL, Torella JC, Wong K, et al. Economic evaluation of a randomized clinical trial of hemodilution with cell salvage in aortic surgery. Br J Surg 2002; 89: 731–6.
13. Ouriel K, Shortell CK, Green RM, DeWeese JA. Intraoperative autotransfusion in aortic surgery. J Vasc Surg 1993; 18: 16–22.
14. Feldman JM, Roth JV, Bjoraker DG. Maximum blood savings by acute normovolemic hemodilution. Anesth Analg 1995; 80: 108–13.
15. Ness PM, Bourke DL, Walsh PC. A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgery. Transfusion 1992; 32: 226–30.
16. Goodnough LT, Grishaber JE, Monk TG, Catalona WJ. Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study of efficacy. Anesth Analg 1994; 78: 932–7.
17. AuBuchon JP. Blood transfusion options: improving outcomes and reducing costs. Arch Pathol Lab Med 1997; 121: 40–7.
18. Bennett Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 1997; 87: 1373–80.
19. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-related viral infections. N Engl J Med 1996; 334: 1685–90.
20. Blumberg N, Kirkley SA, Heal JM. A cost analysis of autologous and allogeneic transfusions in hip-replacement surgery. Am J Surg 1996; 171: 324–30.
21. Vamvakas EC, Carven JH. Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection. Arch Pathol Lab Med 1998; 122: 145–51.
22. American Association of Blood Banks. Standards for perioperative autologous blood collection and administration. Bethesda, MD, 2001: 8.
23. Green DM. Perioperative autologous transfusion service: a logical extension of our role in the operating room. Anesthesiology 1997; 86: 258.
24. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214–35.
© 2004 International Anesthesia Research Society
26. Weiskopf RB. Erythrocyte salvage during cesarean section. Anesthesiology 2000; 92: 1519–22.